ArticleBMC microbiology2025
The effects of postbiotics and glycyrrhetinic acid on immune response and inflammation-related genes during H. pylori eradication therapy.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combined Effect ofFoods (Basel, Switzerland) · 2026Article
- Biotics-based modulation of gastric precancerous states: microbial, metabolic, and epithelial mechanisms.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aims to test the effectiveness of postbiotics from Streptococcus thermophilus and Lactobacillus casei, along with Glycyrrhetinic acid, against H. pylori in both AGS cells (a human gastric adenocarcinoma cell line) and an experimental rat gastritis model.
methodThe effectiveness of the compounds (postbiotics and G. acid) against H. pylori was evaluated by measuring the expression levels of various genes, including NF-κB, IL-1β, IL-6, IL-8, IL-10, TNF-α, COX-2, FOX-M1, and IL-33 in AGS cells using the Real-Time PCR method. Additionally, bacterial loads in gastric tissue were quantified using culture-based colony-forming unit (CFU) analysis and expressed as log₁₀ CFU/g. The study also evaluated the effectiveness of combinations of these components in the rat gastritis model through microbiological and histopathological analyses.
resultsThe postbiotics of S. thermophilus and L. casei have shown a significant reduction in the expression level of NF-κB when compared to the control group. The S. thermophilus plus L. casei treatment group showed a 10-fold decrease in NF-κB expression, while the G. acid plus L. casei treatment group showed a 5-fold decrease. TNF-α expression levels were also lower in the S. thermophilus and L. casei treatment groups with 10-fold and 5-fold reductions, respectively. The expression of IL-1β was significantly reduced in all treatment groups compared to the control group, with a 10-fold decrease in expression. The S. thermophilus plus L. casei treatment group exhibited a 10-fold reduction in IL-6 release, a proinflammatory cytokine. Similarly, the expression of IL-8 was reduced by 10-fold and 2-fold in the S. thermophilus and L. casei treatment groups, respectively. Additionally, bacterial loads in gastric tissue were quantified using culture-based colony-forming unit (CFU) analysis and expressed as log₁₀ CFU/g. The mean bacterial load in the infected control group was 6.14 ± 0.18 log₁₀ CFU/g, while the quaternary treatment group (S. thermophilus + L. casei + G. acid + antibiotic) achieved complete eradication with no detectable colonies (0.00 ± 0.00 log₁₀ CFU/g). Ternary and binary treatment groups exhibited intermediate bacterial loads, ranging from approximately 1.63 ± 0.09 to 3.24 ± 0.17 log₁₀ CFU/g, indicating partial efficacy compared to the control group.
conclusionThese promising findings can pave the way for the development of novel therapeutic approaches for treating H. pylori-associated gastritis. The combination of molecular (gene expression) and microbiological (CFU) data demonstrates the multi-dimensional efficacy of postbiotics and glycyrrhetinic acid as potential adjunctive agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.